Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Onyx Therapeutics, Inc. v. CIPLA Limited et al
Case Number:
1:16-cv-00988
Court:
Nature of Suit:
Judge:
Firms
- Connolly Gallagher
- Gordon Rees
- Greenberg Traurig
- Kratz & Barry
- Morris James
- Morris Nichols
- O'Melveny & Myers
- Phillips McLaughlin
- Potter Anderson
- Richards Layton
- Shaw Keller
- Smith Katzenstein
Companies
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Breckenridge Pharmaceutical Inc.
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- Fresenius Kabi AG
- Sagent Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
-
May 05, 2020
Amgen Comes Out On Top After Bench Trial Over Cancer Drug
Amgen Inc. may have staved off generic competition for its injectable anti-cancer drug Kyprolis for another seven years, after a Delaware federal judge refused to declare a trio of patents tied to the drug invalid.
-
May 06, 2019
Apotex, Fresenius Kabi Settle Amgen's Cancer Drug IP Suit
Apotex Inc., Fresenius Kabi USA Inc. and Sagent Pharmaceuticals Inc. have all agreed to hold off on their generic versions of Amgen Inc.'s cancer treatment Kyprolis, bringing an end to patent infringement litigation against them in Delaware federal court.
-
February 21, 2019
Onyx's Patent Agent Privilege Claim Fails In Cancer Drug Row
Onyx Therapeutics Inc., which is locked in a dispute with generic-drug makers over the cancer treatment Kyprolis, must turn over certain emails and communications related to drug research, after a Delaware federal judge found they are not protected by the "narrow" patent agent privilege.